We could not find any results for:
Make sure your spelling is correct or try broadening your search.
By Chris Wack Immutep Ltd. said Friday it had a successful Type C meeting with the U.S. Food and Drug Administration regarding late-stage clinical development plans for its first-in-class soluble...
By Chris Wack Immutep Ltd. said Tuesday that the U.S. Food and Drug Administration granted fast track designation to eftilagimod alpha IMP321 in combination with pembrolizumab for the treatment of...
By Chris Wack Immutep Limited is in a new collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, for a Phase I/IIa clinical trial in patients with solid tumors. The biotechnology...
By Michael Dabaie Immutep Ltd. said interim data was positive from its ongoing Phase II TACTI-002 study. ADRs were down 1% to $3.00 premarket. The data relates to use of the company's lead...
NEW YORK, May 21 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (OTC:IMMP) announced today that the Company expects to begin trading its common stock on the Pink OTC Markets quotation...
NEW YORK, April 21 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Amex: IMM) announced today that the Company is reorganizing its R&D operations. This restructuring will direct...
NEW YORK, April 3 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Amex: IMM) announced today that it has made an investment in Gold Avenue Ltd., a privately-held Hong Kong company...
NEW YORK, April 2 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE AMEX: IMM) today announced that on March 27, 2009, the Company received notice from the NYSE Amex LLC (the...
NEW YORK, Feb. 27 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Alternext US: IMM.BC) today announced that the Company has signed a Memorandum of Understanding (MOU) confirming...
NEW YORK, Feb. 13 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Alternext US: IMM) announced today that the Company will postpone the quarterly update conference call scheduled...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -10.6666666667 | 0.375 | 0.385 | 0.33 | 3122707 | 0.36036204 | DE |
4 | 0.03 | 9.83606557377 | 0.305 | 0.385 | 0.285 | 3106159 | 0.33013655 | DE |
12 | 0 | 0 | 0.335 | 0.385 | 0.27 | 3192125 | 0.31640369 | DE |
26 | -0.065 | -16.25 | 0.4 | 0.44 | 0.23 | 4352130 | 0.33048896 | DE |
52 | -0.01 | -2.89855072464 | 0.345 | 0.485 | 0.23 | 3115254 | 0.35241647 | DE |
156 | -0.14 | -29.4736842105 | 0.475 | 0.52 | 0.225 | 1859425 | 0.34213065 | DE |
260 | 0.085 | 34 | 0.25 | 0.725 | 0.1 | 2097311 | 0.36718835 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions